doi: 10.1503/cmaj.202169-f.
Conflict of interest statement
Competing interests: Richard Huntsman and Lauren Kelly are co-chairs of Health Canada’s Scientific Advisory Committee on Health Products Containing Cannabis; the opinion of the Committee is neither reflected nor guaranteed in this article. Lauren Kelly holds a Mitacs Accelerate Fellowship in Partnership with Canopy Growth, unrelated to this manuscript. Juan Pablo Appendino declares to have received honoraria from Pendopharm, Sunovion and UCB; he is also a member of committees or boards of the Canadian League Against Epilepsy, the Canadian Society for Clinical Neurophysiology, the Federation of Neurological Sciences of Canada, and the Ibero-American Academy of Pediatric Neurology. Richard Bélanger is a member of the Canadian Pediatric Society’s Cannabis Committee. Bruce Crooks says he served on the Data Security Oversight Committee for the ReRAD study and is a member of the Nova Scotia Advisory Board and the Childhood Wishes Canada Foundation Medical Advisory Board. Evan Lewis is a Volunteer Medical Advisor with JMCC Canada Corp. and declares to have received fees from Spectrum Therapeutics. Alexander Repetski worked as a volunteer consultant with Strainprint. Michael Rieder is a member of the Drug Safety Oversight Committee for a study on the use of medical cannabis to treat headache in children, and is the lead author of the Canadian Pediatric Society position statement on medical cannabis in children. Régis Vaillancourt states that he received consulting fees from Harvest Medicine. No funding has been provided for the writing of this manuscript. No further interest was declared.
